Health Care/Hospital
Alphamab Oncology Presented the Latest Clinical Data from Two Studies on Anti-HER2 Bispecific ADC JSKN003 at the ESMO Congress 2024
SUZHOU, China, Sept. 16, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the latest clinical data from two studies on anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 were presented at the 2024 European Society for Medical Oncology Congress (ESMO Congress 202...
2024-09-16 13:03
1957
"Transfersome Gel" a New Solution for Hypertrophic Scars Chula Pharmacy's Latest Innovation
BANGKOK, Sept. 16, 2024 /PRNewswire/ -- Lecturers at the Faculty of
Pharmaceutical Sciences,Chulalongkorn University
2024-09-16 10:00
1858
ESMO 2024 - ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients
SHENZHEN, China, Sept. 15, 2024 /PRNewswire/ -- ImmVira announced the latest clinical results for its lead oncolytic virus product, MVR-T3011, via intravesical administration in patients with high-risk BCG-failure non-muscle invasive bladder cancer (NMIBC). The results were published through post...
2024-09-15 17:53
3132
Akeso Published Ivonescimab plus Ligufalimab as First-Line Treatment for PD-L1-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at ESMO 2024
Head-to-Head Phase 3 Trial Compared to Pembrolizumab Initiated HONG KONG, Sept. 15, 2024 /PRNewswire/ -- At the 2024 European Society for Medical Oncology (ESMO) Conference, Akeso released the Phase 2 clinical results of its internally developed PD-1/VEGF bispecific antibody, ivonescimab, with or...
2024-09-15 15:10
2939
Dialogue with CGT Leaders! You Are Invited to Join the "2024 GenScript Biotech Global Forum•London" to Discuss the Future Together
PISCATAWAY, N.J., Sept. 14, 2024 /PRNewswire/ -- The year 2024 marks a milestone year for continuous advancements in Cell and Gene Therapy (CGT). The global launch of Amtagvi, a Tumor-Infiltrating Lymphocyte (TIL) therapy, has ushered in a new era for solid tumor treatment using cell therapy. PM3...
2024-09-15 06:53
1952
Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration
NANJING, China, Sept. 14, 2024 /PRNewswire/ -- On September 2, 2024, Simcere Pharmaceuticals Group Ltd. (2096.HK) announced that Sanbexin Sublingual Tablets (Edaravone and Dexborneol sublingual tablets), an innovative drug for stroke, has been granted the Breakthrough Therapy designation by the U...
2024-09-14 19:43
3493
Gan & Lee Pharmaceuticals Presented Two Positive Clinical Results of Once-weekly Insulin GZR4 at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD 2024)
* In Phase Ia clinical study, GZR4 demonstrated favorable safety and tolerability profiles in healthy subjects, maintaining a stable glucose-lowering effect for up to one week with a single administration. * In Phase Ib clinical study, patients with Type 2 diabetes mellitus (T2DM) receiving s...
2024-09-14 19:00
4010
Harbour BioMed Announces the Latest Clinical Data on the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Sept. 14, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immuno...
2024-09-14 16:06
3565
NiceTop™️ Unveils New Hair Growth Supplement Amid Product Line Expansion
PLEASANTON, Calif., Sept. 13, 2024 /PRNewswire/ -- NiceTop™️, a U.S.-based anti-aging research team, has launched a new hair growth supplement, marking its latest foray into the personal care and nutrition market. The NiceTop™️ brand team, founded in 2012, announced the release of NiceTop™️ Hair...
2024-09-14 12:21
1265
Live from ESMO 2024 | Ascentage Pharma Releases Latest Data Showing Sustained Clinical Efficacy of Olverembatinib in SDH-Deficient GIST during a Mini Oral Presentation
ROCKVILLE, Md. and SUZHOU, China, Sept. 14, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has released t...
2024-09-14 08:18
3739
MediLink presents YL201 (B7H3 ADC) at ESMO 2024, with over 6-months PFS in SCLC, and showing pan-tumor benefits
* The first publication of clinical data for YL201, featured in an oral presentation at ESMO 2024. * Encouraging antitumor activity of YL201 in multiple solid tumor types, including SCLC, NPC, and wild-type NSCLC, from Phase I escalation and expansion results. * In extensive-stage SCLC pati...
2024-09-14 01:00
2993
111 Inc. Announces Its Co-founders' Strategic Share Purchase and Highlights Continued Growth and Innovation
SHANGHAI, Sept. 13, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream inChina, today was informed by co-founders...
2024-09-13 19:30
5124
Opening Ceremony of BMC France Office
LILLE, France, Sept. 13, 2024 /PRNewswire/ -- On September 12, 2024, BMC held a grand opening ceremony at its new office in Marcq-en-Barœul,France. Employees from acrossEurope and members of the company leadership team attended this event. During the celebration, George Zhuang, President and Gen...
2024-09-13 19:13
978
GSK shingles vaccine now available in Malaysia
A vaccine for the prevention of shingles in adults aged 50 and over and those aged 18 and over at increased risk KUALA LUMPUR, Malaysia, Sept. 13, 2024 /PRNewswire/ -- GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced the launch of its Herpes Zoster vaccine,Shingrix (MAL24056002ARZ), ...
2024-09-13 15:07
2116
US FDA Grants RPD Designation to Senhwa Biosciences Silmitasertib for Pediatric Neuroblastoma
TAIPEI and SAN DIEGO, Sept. 13, 2024 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that its new drug Silmitasertib (CX-4945) was granted a rare pe...
2024-09-13 13:49
1091
VOCAL CORD PARALYSIS AND THYROID CANCER SURVIVOR LAUNCHES 'FIND YOUR VOICE' PROGRAMME AND WORLD'S FIRST BILINGUAL NLP COURSE
* Using NLP Techniques to Help Individuals Overcome Their Fears and Gain Confidence to Speak Out * Singapore Company, Weislin Education Enterprise, To Launch World's First Bilingual NLP Programme SINGAPORE, Sept. 13, 2024 /PRNewswire/ -- Coach Vincent Lim, founder of Weislin Education Enterp...
2024-09-13 12:31
1905
Nona Biosciences Enters into Collaboration Agreement with Umoja Biopharma to Advance In Vivo CAR-T Cell Therapies
CAMBRIDGE, Mass., Sept. 12, 2024 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), announced today that it has entered into a multi-target antibody discovery collaboration with Umoja Biopharma, a transformative immunotherapy...
2024-09-13 09:27
1410
BeiGene Singapore Raises Awareness for World Lymphoma Awareness Day 2024: It's Time for Honest Talk
SINGAPORE, Sept. 13, 2024 /PRNewswire/ -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, is proud to join the global community in raising awareness about lymphoma on World Lymphoma Awareness Day (WLAD). Lymphoma, a type of blood cancer affecting millions of peo...
2024-09-13 09:00
2072
Aurora Biosynthetics Launches to Revolutionize RNA Therapeutics Manufacturing
SYDNEY, Sept. 13, 2024 /PRNewswire/ -- Aurora Biosynthetics, a pioneering advanced RNA therapeutics manufacturing company, announced its official launch. This heralds a new era in RNA therapeutics manufacturing across theAsia-Pacific region. Aurora Biosynthetics is poised to meet the surging dema...
2024-09-13 04:00
2310
Stapokibart Was Granted Marketing Approval From National Medical Products Administration For The Treatment Of Moderate-to-severe Atopic Dermatitis in Adults
CHENGDU, China, Sept.12, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") ofChina has recently approved the new drug application for Stapokibart (anti-IL-4Rα monoclonal antibody, trade name:Kangyueda (康悦达), for th...
2024-09-13 00:07
1743
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Strategic Forum in Chongqing Drives Expansion of New Western Land-Sea Corridor
2024-11-16 14:15
5216
